


Applicants: Guy Benchley et al.
 Application No.: 10/809,946

AMENDMENTS TO THE CLAIMS

Please replace all prior versions and listings of claims with the amended claims as follows:

1. (Currently amended) A compound of formula (I):




or a pharmaceutically acceptable salt thereof, wherein:

R^1 and R^2 are each independently R, halogen, CN, NO₂, or TR, ~~or R^1 and R^2 taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from N, O, or S;~~

T is an optionally substituted C₁-C₄ alkylidene chain wherein up to two methylene units of T are optionally and independently replaced by O, N(R), C(O), S, SO, or SO₂;

Ar¹ is



wherein each occurrence of QR⁵ is, independently, CH₂halogen, halogen, CH₂CN, CN, CH₂CO₂R', CO₂R', CH₂COR', COR', R', CH₂NO₂, NO₂, CH₂OR', OR', CH₂SR', SR', haloalkyl, CH₂SO₂N(R')₂, SO₂N(R')₂, CH₂N(R')₂, N(R')₂, NHCOR', CH₂NHCOR', CH₂PO(OR')₂, PO(OR')₂

~~an optionally substituted ring selected from: an aryl group selected from a 5-6 membered monocyclic or an 8-10 membered bicyclic ring having 0-5 heteroatoms~~

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

~~independently selected from nitrogen, oxygen, or sulfur; a 3-8 membered saturated or partially unsaturated ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or an 8-10 membered saturated or partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Ar¹ is optionally substituted at one or more carbon atoms with 0-5 occurrences of -Q-R⁵, and at one or more substitutable nitrogen atoms with -R⁶ and each occurrence of R⁶ is independently R', -COR', -CO₂(C₁₋₆ aliphatic), -CON(R')₂, -SO₂N(R')₂, or -SO₂R';~~

R³ and R⁴ are each independently Z-R⁷, or R³ and R⁴ are taken together to form an optionally substituted saturated, partially unsaturated, or fully unsaturated 3-8 membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur wherein said ring is optionally substituted with 0-5 independent occurrences of Y-R⁸;

each occurrence of Q, Z, and Y is independently a bond or an optionally substituted C₁₋₆ alkylidene chain wherein up to two non-adjacent methylene units of Q and up to three non-adjacent methylene units of Z are optionally replaced by CO, CO₂, COCO, CONR, OCONR, NRNR, NRNRCO, NRCO, NRCO₂, NRCONR, SO, SO₂, NRSO₂, SO₂NR, NRSO₂NR, O, S, or NR;

each occurrence of R⁵, R⁷ and R⁸ is independently R', halogen, NO₂, CN, OR', SR', N(R')₂, NR'C(O)R', NR'C(O)N(R')₂, NR'CO₂R', C(O)R', CO₂R', OC(O)R', C(O)N(R')₂, OC(O)N(R')₂, SOR', SO₂R', SO₂N(R')₂, NR'SO₂R', NR'SO₂N(R')₂, PO(OR')₂, C(O)C(O)R', or C(O)CH₂C(O)R'; and

each occurrence of R is independently hydrogen or an optionally substituted C₁₋₆ aliphatic group; and each occurrence of R' is independently hydrogen or an optionally substituted group selected from C₁₋₈ aliphatic, C₆₋₁₀ aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 3-10 ring atoms, or wherein two occurrences of R taken together, R and R' taken together, or two occurrences of R' taken together, form an optionally substituted saturated,

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

partially unsaturated, or fully unsaturated 3-8 membered ring having 0-3
 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
 provided that [[:]]

- [[i)]] R^3 and R^4 are not simultaneously hydrogen; and
 ii) — when R^3 and R^4 are both methyl, or R^3 is methyl and R^4 is $(CH_2)_2OH$,
 then Ar^1 is not 3,4,5-trimethoxyphenyl.

2-6. (Canceled)

7. (Currently amended) The compound of claim 1, wherein both
~~occurrences of $Q-R^5$ are methyl Q is independently a bond or is an optionally~~
~~substituted C_1-C_4 alkylidene chain wherein up to two non-adjacent methylene units of~~
 ~~Q are optionally replaced by CO , CO_2 , $CONR$, $OCONR$, $NRCO$, $NRCO_2$, $NRSO_2$,~~
 ~~SO_2NR , O , S , or NR ; and each occurrence of R^5 is independently selected from R' ,~~
~~halogen, NO_2 , CN , OR' , SR' , $N(R')_2$, $NR'C(O)R'$, $NR'C(O)N(R')_2$, $NR'CO_2R'$,~~
 ~~$C(O)R'$, CO_2R' , $OC(O)R'$, $C(O)N(R')_2$, $OC(O)N(R')_2$, SOR' , SO_2R' , $SO_2N(R')_2$,~~
 ~~$NR'SO_2R'$, $NR'SO_2N(R')_2$, $PO(OR')_2$, $C(O)C(O)R'$, or $C(O)CH_2C(O)R'$, and x is 0,~~
~~1, 2, or 3.~~

8. (Currently amended) The compound of claim 1, wherein at least one
~~occurrence of $Q-R^5$ is CF_3 $Q-R^5$ substituents on Ar^1 are CH_2 halogen, halogen,~~
 ~~CH_2CN , CN , CH_2CO_2R' , CO_2R' , CH_2COR' , COR' , R' , CH_2NO_2 , NO_2 , CH_2OR' ,~~
 ~~OR' , CH_2SR' , SR' , haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$,~~
 ~~$NHCOR'$, CH_2NHCOR' , $CH_2PO(OR')_2$, $PO(OR')_2$ or two adjacent occurrences of~~
 ~~$Q-R^5$, taken together with the atoms to which they are bound, form an optionally~~
~~substituted saturated, partially unsaturated, or fully unsaturated 5-8 membered ring~~
~~having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur.~~

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

9. (Original) The compound of claim 1, wherein Q-R⁵ substituents on Ar¹ are fluoro, iodo, chloro, bromo, COCH₃, CO₂CH₃, C₁₋₄alkyl, NH₂, CH₂NH₂, NHMe, CH₂NHMe, N(Me)₂, CH₂N(Me)₂, N(Et)₂, CH₂N(Et)₂, NH(phenyl), CO(C₁₋₄alkyl), CH₂CO(C₁₋₄alkyl), NHCO(C₁₋₄alkyl), CH₂NHCO(C₁₋₄alkyl), CN, CH₂CN, OH, C₁₋₄alkoxy, optionally substituted benzyloxy, optionally substituted phenyloxy, CF₃, SO₂NH₂, SO₂NHMe, optionally substituted SO₂(phenyl), SO₂(C₁₋₄alkyl), CONH₂, CH₂PO(OR')₂, or an optionally substituted group selected from a saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

10. (Currently amended) The compound of claim 1, wherein R¹ and R² groups of formula I are each independently hydrogen, N(R)₂, SR, or OR, ~~or TR, or R¹ and R³, taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S.~~

11. (Currently amended) The compound of claim 1, wherein R¹ and R² groups are each independently hydrogen, OH, CH₃, CH₂CH₃, OCH₃, CH₂OH, CH₂OCH₃, CH₂NH₂, CH₂NHCH₃, NH₂, or CH₂NH₂, ~~or R¹ and R³, taken together, form a fused optionally substituted pyrrolyl, pyrazolyl, or imidazolyl ring.~~

12. (Currently amended) The compound of claim 1, wherein R³ and R⁴ are each independently Z-R⁷ wherein Z is a bond or an optionally substituted C₁₋₄ [[C₀₋₄]] alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, NRCO₂, NRSO₂, CONR, C(O), C(O)O, and wherein R⁷ is selected from halogen, CN, N(R')₂, NHCOR', or R', ~~or wherein R³ and R⁴, taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.~~

Applicants: Guy Benchley et al
 Application No.: 10/809,946

13. (Currently amended) The compound of claim 1, wherein R^3 and R^4 are each independently hydrogen, CN, halogen, OH, SH, NH_2 , CO_2H , COH, $CONH_2$, SO_2NH_2 , NO_2 , or $(CH_2)_nNRR^7$, wherein R and R^7 , taken together with the nitrogen atom to which they are bound, form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, ~~or R^3 and R^4 , taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and n is 0, 1, 2, 3, 4, or 5.~~

14. (Currently amended) The compound of claim 1, wherein one of R^3 or R^4 is hydrogen, and the other of R^3 or R^4 is ~~$(CH_2)_n$ halogen, $(CH_2)_nCN$, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nCH_3$, or $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$, wherein R^7 is hydrogen, $(CH_2)_mN(R')_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl or ~~alkyl~~, heteroaryl, wherein each of n and m is 0 or 1, or heteroalkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur.~~

15. (Original) The compound of claim 14, wherein R^3 is hydrogen.

16. (Original) The compound of claim 14, wherein R^4 is hydrogen.


17. (Original) The compound of claim 1, wherein R^3 and R^4 , taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5- or 6-membered ring having 0-3

Applicants: Guy Benchley et al.
 Application No.: 10/809,946


heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein said ring is optionally substituted with 0, 1, 2, 3, 4, or 5 occurrences of Y-R⁸.

18. (Original) The compound of claim 17, wherein each occurrence of Y-R⁸ is independently methyl, ethyl, t-butyl, fluoro, chloro, bromo, oxo, CF₃, OMe, OEt, CN, SO₂Me, SO₂NH₂, NH₂, NHMe, N(Me)₂, SMe, SEt, OH, C(O)Me, NO₂, or CH₂OH.


19. (Original) The compound of claim 1, having one of formulas I-A-i, I-A-ii, I-B-i, I-B-ii, I-C-i, I-C-ii, I-D-i, or I-E-i:




I-A-i



I-A-ii




I-B-i




I-B-ii


Applicants: Guy Benchley et al.
 Application No.: 10/809,946




I-C-i



I-C-ii



I-D-i



I-E-i

wherein q is 0-5.

20-30. (Canceled)

31. (Currently amended) The compound of claim 19 [[25]], wherein R^3 is $Z-R^7$, wherein Z is a bond or is an optionally substituted C_{1-4} [[C₀₋₄]] alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, NRCO₂, NRSO₂, CONR, C(O), C(O)O, and wherein R^7 is halogen, CN, $N(R')_2$, NHCOR', or R' .

32. (Currently amended) The compound of claim 19 [[25]], wherein R^3 is ~~$(CH_2)_n$ halogen, $(CH_2)_n$ CN, $(CH_2)_n$ OR⁷, $(CH_2)_n$ NRR⁷, $(CH_2)_n$ C(O)R⁷, $(CH_2)_n$ C(O)R⁷~~ $(CH_2)_n$ CH₃, or $(CH_2)_n$ C(O)NRR⁷, $(CH_2)_n$ SR⁷, wherein R^7 is hydrogen, $(CH_2)_m$ N(R')₂,

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl ~~or -alkyl~~, heteroaryl, wherein each of n and m is 0 or 1, or heteroalkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

33. (Currently amended) The compound of claim 19 [[25]], wherein Z is a bond or is an optionally substituted C_{1-4} [[C_{0-4}]] alkylidene chain wherein one methylene unit of Z is optionally replaced by O, NR, NRCO, NR CO_2 , NRSO $_2$, CONR, C(O), C(O)O, and wherein R^7 is selected from halogen, CN, $N(R')_2$, NHCOR', or R' .

34. (Currently amended) The compound of claim 19 [[25]], wherein R^4 is ~~$(CH_2)_n$ halogen, $(CH_2)_n$ CN, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nCH_3$, or $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$~~ , wherein R^7 is hydrogen, $(CH_2)_mN(R')_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl ~~or -alkyl~~, heteroaryl, wherein each of n and m is 0 or 1, or heteroalkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

35. (Currently amended) The compound of claim 19 [[25]], wherein q is 0, 1, or 2, and each occurrence of $Y-R^8$ is independently methyl, ethyl, t-butyl, fluoro, chloro, bromo, oxo, CF_3 , OMe, OEt, CN, SO_2Me , SO_2NH_2 , NH_2 , NHMe, $N(Me)_2$, SMe, SEt, OH, C(O)Me, NO_2 , or CH_2OH .

36. (Currently amended) The compound of claim 19 [[25]], wherein compounds have one of formulas II-A-i, II-B-i, or II-C-i, and the compound variables are defined as:

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

a) x is 0, 1, 2, or 3, and $Q-R^5$ is CH_2 halogen, halogen, CH_2CN , CN , CH_2CO_2R' , CO_2R' , CH_2COR' , COR' , R' , CH_2NO_2 , NO_2 , CH_2OR' , OR' , CH_2SR' , SR' , haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, $NHCOR'$, CH_2NHCOR' , $CH_2PO(OR')_2$, $PO(OR')_2$, or $Q-R^5$, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;

b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR , OR , or TR , or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S; and

c) R^3 is $(CH_2)_n$ halogen, $(CH_2)_nCN$, $(CH_2)_nOR^7$, $(CH_2)_nNRR^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nC(O)R^7$, $(CH_2)_nCH_3$, $(CH_2)_nC(O)NRR^7$, $(CH_2)_nSR^7$, wherein R^7 is $(CH_2)_mN(R')_2$, C_1 - C_4 alkyl, an optionally substituted 5- or 6-membered aryl, aralkyl, heteroaryl, or heteroaralkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

37. (Currently amended) The compound of claim 19 [[25]], wherein compounds have one of formulas II-A-ii, II-B-ii, or II-C-ii, and one or more of the compound variables are defined as:

a) x is 0, 1, 2, or 3, and $Q-R^5$ is CH_2 halogen, halogen, CH_2CN , CN , CH_2CO_2R' , CO_2R' , CH_2COR' , COR' , R' , CH_2NO_2 , NO_2 , CH_2OR' , OR' , CH_2SR' , SR' , haloalkyl, $CH_2SO_2N(R')_2$, $SO_2N(R')_2$, $CH_2N(R')_2$, $N(R')_2$, $NHCOR'$, CH_2NHCOR' , $CH_2PO(OR')_2$, $PO(OR')_2$, or $Q-R^5$, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR, or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S; and

c) R^4 is $(CH_2)_n\text{halogen}$, $(CH_2)_n\text{CN}$, $(CH_2)_n\text{OR}^7$, $(CH_2)_n\text{NRR}^7$, $(CH_2)_n\text{C(O)R}^7$, $(CH_2)_n\text{C(O)R}^7(CH_2)_m\text{CH}_3$, $(CH_2)_n\text{C(O)NRR}^7$, $(CH_2)_n\text{SR}^7$, wherein R^7 is $(CH_2)_m\text{N(R')}_2$, $\text{C}_1\text{-C}_4\text{alkyl}$, an optionally substituted 5- or 6-membered aryl, aralkyl, heteroaryl, or heteroaralkyl group, or R and R^7 , taken together with the nitrogen atom to which they are bound form an optionally substituted 3-8-membered saturated or partially unsaturated ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur, n is 0 or 1, and m is 0 or 1.

38. (Currently amended) The compound of claim 19 [[25]], wherein compounds have formula II-E-i, and one or more of the compound variables are defined as:


a) x is 0, 1, 2, or 3, and $Q\text{-R}^5$ is $\text{CH}_2\text{halogen}$, halogen, CH_2CN , CN, $\text{CH}_2\text{CO}_2\text{R}'$, $\text{CO}_2\text{R}'$, $\text{CH}_2\text{COR}'$, COR' , R' , CH_2NO_2 , NO_2 , $\text{CH}_2\text{OR}'$, OR' , $\text{CH}_2\text{SR}'$, SR' , haloalkyl, $\text{CH}_2\text{SO}_2\text{N(R')}_2$, $\text{SO}_2\text{N(R')}_2$, $\text{CH}_2\text{N(R')}_2$, N(R')_2 , NHCOR' , $\text{CH}_2\text{NHCOR}'$, $\text{CH}_2\text{PO(OR')}_2$, PO(OR')_2 , or $Q\text{-R}^5$, taken together with the atoms to which they are bound, form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-8-membered ring having 0-3 heteroatoms selected from nitrogen, oxygen, or sulfur;

b) R^1 and R^2 are each independently hydrogen, $N(R)_2$, SR, OR, or TR, or R^1 and R^2 , taken together form an optionally substituted saturated, partially unsaturated, or fully unsaturated 5-membered ring having 0-2 heteroatoms independently selected from N, O, or S; and




c) q is 0, 1, or 2, and each occurrence of $Y\text{-R}^8$ is independently methyl, ethyl, t-butyl, fluoro, chloro, bromo, cxo, CF_3 , OMe, OEt, CN, SO_2Me , SO_2NH_2 , NH_2 , NHMe, N(Me)_2 , SMe, SEt, OH, C(O)Me , NO_2 , or CH_2OH .

Applicants: Guy Benchley et al.
Application No.: 10/809,946




39. (Currently amended) The compound of claim 19 [[25]], The compound of claim 1, selected from:












Applicants: Guy Benchley et al.
Application No.: 10/809,946




Applicants: Guy Benchley et al.
Application No.: 10/809,946



Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-28****I-29****I-30****I-31****I-32****I-33****I-34****I-35****I-36**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-37

I-38


I-39




I-40




I-41




I-42



I-43












I-44












I-45









Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-46****I-47****I-48****I-49****I-50****I-51****I-52****I-53****I-54**










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-55****I-56****I-57****I-58****I-59****I-60****I-61****I-62****I-63**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-64****I-65****I-66****I-67****I-68****I-69**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

I-70**I-71****I-72****I-73****I-74****I-75****I-76****I-77****I-78****I-79****I-80****I-81**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-82




I-83




I-84




I-85




I-86




I-87



I-88






I-89












I-90










Applicants: Guy Benchley et al.
Application No.: 10/809,946












Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-100****I-101****I-102****I-103****I-104****I-105****I-106****I-107****I-108**










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-109****I-110****I-111****I-113****I-114****I-115****I-116****I-117****I-118**










Applicants: Guy Benchley et al.
Application No.: 10/809,946




Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-128****I-129****I-130****I-131****I-132****I-133****I-134****I-135****I-136**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-137****I-138****I-139****I-140****I-141****I-142****I-143****I-144****I-145**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-146




I-147




I-148




I-149




I-150



I-151












I-152












I-153










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-154****I-155****I-156****I-157****I-158****I-159****I-160****I-161****I-162**










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-163****I-164****I-165****I-166****I-167****I-168****I-169****I-170****I-171**










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-172****I-173****I-174****I-175****I-176****I-177****I-178****I-179****I-180**








Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-181****I-182****I-183****I-184****I-185****I-186****I-187****I-188****I-189**










Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-190****I-191****I-192****I-193****I-194****I-195****I-196****I-197****I-198**









Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-199****I-200****I-201****I-202****I-203****I-204****I-205****I-206**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-207****I-208****I-209****I-210****I-211****I-212****I-213****I-214****I-215**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-216****I-217****I-218****I-219****I-220****I-221****I-222****I-223****I-224**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-225




I-226




I-227




I-228




I-229




I-230



I-231




I-232




I-233


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-234




I-235




I-236




I-237




I-238



I-239




I-240




I-241


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-242




I-243




I-244




I-245




I-246




I-247



I-248












I-249










I-250









Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-251****I-252****I-253****I-254****I-255****I-256****I-257****I-258****I-259**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-260****I-261****I-262****I-263****I-264****I-265****I-266**


Applicants: Guy Benchley et al.
Application No.: 10/809,946

**I-267****I-268****I-269****I-270****I-271****I-272****I-273****I-274**


Applicants: Guy Benchley et al.
Application No.: 10/809,946




I-275




I-276




I-277




I-278




I-279




I-280



I-281




I-282




I-283


Applicants: Guy Benchley et al.
 Application No.: 10/809,946



I-284



I-285



I-286

40. (Original) A composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

41. (Canceled)

42. (Original) The composition of claim 40, additionally comprising a therapeutic agent selected from an anti-inflammatory agent, an anti-proliferative agent, an immunomodulatory or immunosuppressive agent, or an agent for treating immunodeficiency disorders.

43. (Currently amended) A method of inhibiting SYK or ZAP-70 kinase activity in:

(a) a patient; or

(b) a biological sample;

which method comprises administering to said patient, or contacting said biological sample with:

a) a composition of claim 40; or

b) a compound of claim 1.

Applicants: Guy Benchley et al.
 Application No.: 10/809,946

44. (Currently amended) A method of treating or lessening the severity of treatment or lessening the severity of lepromatous leprosy ~~an immunodeficiency disorder~~, atopic dermatitis, contact dermatitis, seborrhectic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, epidermolysis bullosa, urticaria, angiodermas, vasculitides, erythemas, cutaneous eosinophilias, uveitis, Alopecia, areata, vernal conjunctivitis, eosinophilia fasciitis ~~inflammatory disease~~, Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, pancreatitis, Crohn's disease, ulcerative colitis, migraine, rhinitis, ~~allergic disease~~, multiple sclerosis, lupus erythematosus, rheumatoid arthritis, type I diabetes, psoriasis, seronegative spondyloarthropathis, Behcet's disease, Siogren's syndrome, systemic sclerosis, Hashimoto's thyroiditis, myasthenia gravis, nephrotic syndrome, idiopathic thrombocytopenia purpura, hyper IgE syndrome ~~autoimmune disease~~, leukemia, lymphoma, Sezary syndrome, restenosis following angioplasty, atherosclerosis ~~proliferative disorder~~, allograft rejection, graft versus host disease ~~immunologically mediated disease~~, or asthma, ~~respiratory disorder~~, comprising the step of administering to said patient:

- a) a composition of claim 40; or
- b) a compound of claim 1.

45. (Currently amended) The method according to claim 41, comprising the additional step of administering to said patient an additional therapeutic agent selected from an anti-inflammatory agent, an anti-proliferative agent, an immunomodulatory or immunosuppressive agent, or an agent for treating immunodeficiency disorders, wherein: said additional therapeutic agent is appropriate for the disease being treated[[:]] and ~~said additional therapeutic agent~~ is administered together with said composition as a single dosage form or separately from said composition as part of a multiple dosage form.

Applicants: Guy Benchley et al.
Application No.: 10/809,946

46. (Currently amended) The method according to claim 44, wherein the disease is multiple sclerosis, lupus erythematosus, rheumatoid arthritis, type I diabetes, psoriasis, seronegative spondyloarthropathis, Behcet's disease, Sjogren's syndrome, systemic sclerosis, Hashimoto's thyroiditis, myasthenia gravis, nephrotic syndrome, idiopathic thrombocytopenia purpura, or hyper IgE syndrome an immune disorder.

47. (Original) The method according to claim 44, wherein the disease is asthma.